TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16261464

Group type: EXPERIMENTAL
Intervention: Landiolol (loading dose of 125 microg kg(‐1) min(‐1) for 1 min followed by an infusion at 40 microg kg(‐1) min(‐1) for 4 min)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 11555220

Group type: EXPERIMENTAL
Intervention: Prescribing training intervention for primary health care nurses
Number of subjects: 457

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 457
Study: 9260344

Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization and Reprocessing (EMDR)
Number of subjects: 21

Group type: COMPARATOR
Intervention: No-treatment wait‐list control
Number of subjects: 21
Study: 8372340

Group type: EXPERIMENTAL
Intervention: Simvastatin (10 mg/d)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Pravastatin (20 mg/d)
Number of subjects: 17
Study: 3553281

Group type: EXPERIMENTAL
Intervention: Vinpocetine 10 mg three times a day for 30 days, then 5 mg three times a day for 60 days
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 2537605

Group type: EXPERIMENTAL
Intervention: CDDP alone
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: CDDP-CQ
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: CDDP-etoposide
Number of subjects: 51
Study: 31475496

Group type: EXPERIMENTAL
Intervention: Tiaoshen Zhitong needling
Number of subjects: 80

Group type: COMPARATOR
Intervention: Routine needling
Number of subjects: 80
Study: 27748006

Group type: EXPERIMENTAL
Intervention: Aliskiren
Number of subjects: 1358

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1358
Study: 25972286

Group type: EXPERIMENTAL
Intervention: Fidaxomicin 200 mg
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 22486331

Group type: EXPERIMENTAL
Intervention: Desire thinking induction
Number of subjects: 45

Group type: COMPARATOR
Intervention: Distraction
Number of subjects: 45

Group type: COMPARATOR
Intervention: Verbal reasoning
Number of subjects: 45
Study: 22191245

Group type: EXPERIMENTAL
Intervention: Vena cava filter placement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conservative therapy alone
Number of subjects: 0
Study: 19101237

Group type: EXPERIMENTAL
Intervention: Group A: 1,000 ml/day of fluid intake, 120 mmol/day sodium, and 250 mg furosemide twice daily
Number of subjects: 410

Group type: COMPARATOR
Intervention: Group B: 1,000 ml/day of fluid intake, 120 mmol/day sodium, and 125 mg furosemide twice daily
Number of subjects: 410

Group type: COMPARATOR
Intervention: Group C: 1,000 ml/day fluid intake, 80 mmol/day sodium, and 250 mg furosemide twice daily
Number of subjects: 410

Group type: COMPARATOR
Intervention: Group D: 1,000 ml/day fluid intake, 80 mmol/day sodium, and 125 mg furosemide twice daily
Number of subjects: 410

Group type: COMPARATOR
Intervention: Group E: 2,000 ml/day fluid intake, 120 mmol/day sodium, and 250 mg furosemide twice daily
Number of subjects: 410

Group type: COMPARATOR
Intervention: Group F: 2,000 ml/day fluid intake, 120 mmol/day sodium, and 125 mg furosemide twice daily
Number of subjects: 410

Group type: COMPARATOR
Intervention: Group G: 2,000 ml/day fluid intake, 80 mmol/day sodium, and 250 mg furosemide twice daily
Number of subjects: 410

Group type: COMPARATOR
Intervention: Group H: 2,000 ml/day fluid intake, 80 mmol/day sodium, and 125 mg furosemide twice daily
Number of subjects: 410
Study: 16216019

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 619

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 619
Study: 15331895

Group type: EXPERIMENTAL
Intervention: 60 mg intravenous Ketorolac
Number of subjects: 24

Group type: COMPARATOR
Intervention: No analgesia (Control)
Number of subjects: 24
Study: 11098157

Group type: EXPERIMENTAL
Intervention: Optimal angle for force development (Lo)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Elbow flexion with forearm in midrange position
Number of subjects: 24
Study: 9117306

Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy (46 Gy 5 days per week in 30‐38 days)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Control group (surgery alone)
Number of subjects: 172
Study: 7691114

Group type: COMPARATOR
Intervention: G-CSF alone
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: G-CSF + quinolone
Number of subjects: 59
Study: 3456148

Group type: EXPERIMENTAL
Intervention: Microlipid supplementation (7% of total calories) for 1 year
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control group (no Microlipid supplementation)
Number of subjects: 13
Study: 29624664

Group type: EXPERIMENTAL
Intervention: Mein Weg (trauma-focused group intervention)
Number of subjects: 99

Group type: COMPARATOR
Intervention: UC (usual care)
Number of subjects: 99
Study: 28339596

Group type: EXPERIMENTAL
Intervention: Graphic health warning (GHW)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Text-only warning
Number of subjects: 142
Study: 26322721

Group type: EXPERIMENTAL
Intervention: Recruitment script that explicitly requested non-registered donors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Elevation induction (morally inspiring story)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Recruitment script that did not list eligibility requirements
Number of subjects: 0
Study: 23000049

Group type: EXPERIMENTAL
Intervention: Augmented group (1ml Vertecem V+ injected in each screw hole before screw positioning)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Non-augmented group (fixed using LCP DF without augmentation)
Number of subjects: 12
Study: 21180677

Group type: EXPERIMENTAL
Intervention: 0.025% hyaluronan-containing mouthwash
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine
Number of subjects: 45

Group type: COMPARATOR
Intervention: Water-based mouthwash (negative control)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: In vitro effects on bacteria
Number of subjects: 45
Study: 18211656

Group type: EXPERIMENTAL
Intervention: Structured pharmaceutical care service (including education and introduction of intensive self‐monitoring)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Traditional services
Number of subjects: 165
Study: 16322118

Group type: EXPERIMENTAL
Intervention: Oral cyclophosphamide (50 mg daily) and methotrexate (2.5 mg twice daily on days 1 and 4)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Oral cyclophosphamide (50 mg daily) and methotrexate (2.5 mg twice daily on days 1 and 4) plus thalidomide (200 mg daily)
Number of subjects: 171
Study: 12560954

Group type: COMPARATOR
Intervention: Weightlifters (WL)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Powerlifters (PL)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sprinters (S)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Non-athletes (NA)
Number of subjects: 20
Study: 10098569

Group type: EXPERIMENTAL
Intervention: Clindamycin‐Primaquine (CP)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Trimethoprim‐Sulfamethoxazole (TS)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Dapsone‐Trimethoprim (DT)
Number of subjects: 145
Study: 7566230

Group type: EXPERIMENTAL
Intervention: Parents of children with Down's syndrome
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control parents
Number of subjects: 110
Study: 1704880

Group type: EXPERIMENTAL
Intervention: Radiation therapy
Number of subjects: 0
Study: 7340274

Group type: EXPERIMENTAL
Intervention: Tobramycin-clindamycin
Number of subjects: 47

Group type: COMPARATOR
Intervention: Cephalothin followed by cephalexin
Number of subjects: 47
Study: 31468237

Group type: EXPERIMENTAL
Intervention: Focal muscle vibration (fMV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Whole body vibration (WBV)
Number of subjects: 0
Study: 29020479

Group type: EXPERIMENTAL
Intervention: Topical silicone gel applied after Er:YAG laser treatment
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo applied after Er:YAG laser treatment
Number of subjects: 19
Study: 26923831

Group type: EXPERIMENTAL
Intervention: Silicone intranasal splints removed on the fifth postoperative day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Silicone intranasal splints removed on the seventh postoperative day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Silicone intranasal splints removed on the tenth postoperative day
Number of subjects: 0
Study: 24786930

Group type: EXPERIMENTAL
Intervention: Resistive home exercise (12 weeks, 5 days/week) followed by twice-a-week home or gym exercise (12 weeks)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Range of motion exercise (24 weeks, 5 days/week)
Number of subjects: 19
Study: 22402568

Group type: EXPERIMENTAL
Intervention: CPAP/INSURE
Number of subjects: 256

Group type: COMPARATOR
Intervention: Oxygen/MV
Number of subjects: 256
Study: 20465148

Group type: EXPERIMENTAL
Intervention: Environmental intervention to alter school environment for healthier eating and physical activity (18 months)
Number of subjects: 77
Study: 19101898

Group type: EXPERIMENTAL
Intervention: Urine nuclear matrix protein 22 (NMP22) measurement
Number of subjects: 151

Group type: COMPARATOR
Intervention: Control group (participants without TCC)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: NMP22 for detecting stage Ta tumors
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: NMP22 for detecting grade 1 tumors
Number of subjects: 151
Study: 15674301

Group type: EXPERIMENTAL
Intervention: Soy-based meal replacement (MR)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Individualized diet plan (IDP)
Number of subjects: 104
Study: 11837933

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg twice daily
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo twice daily
Number of subjects: 47
Study: 9840102

Group type: EXPERIMENTAL
Intervention: Topical glucocorticosteroids (hydrocortisone acetate foam preparation, 100 mg b.i.d.)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (patients without intestinal inflammation)
Number of subjects: 19
Study: 8134189

Group type: EXPERIMENTAL
Intervention: Breast milk (with native lactoferrin)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Lactoferrin-free breast milk
Number of subjects: 8
Study: 2673795

Group type: EXPERIMENTAL
Intervention: CHF 1194
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Piroxicam
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 1091216

Group type: EXPERIMENTAL
Intervention: Fluprednylidene acetate cream applied once daily plus cream base of the same formulation twice daily
Number of subjects: 31

Group type: COMPARATOR
Intervention: Fluprednylidene acetate cream applied 3 times daily
Number of subjects: 31

Group type: COMPARATOR
Intervention: Betamethasone 17-valerate cream applied 3 times daily
Number of subjects: 31
Study: 31037773

Group type: EXPERIMENTAL
Intervention: Infliximab treatment group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 0
Study: 29226134

Group type: EXPERIMENTAL
Intervention: Biodentine (BD)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: MTA‐Plus (MTA‐P)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: ProRoot MTA (PR‐MTA)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Ferric sulfate (FS)
Number of subjects: 29
Study: 26107852

Group type: EXPERIMENTAL
Intervention: Competency-based training intervention for DSPs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no training intervention)
Number of subjects: 0
Study: 23563444

Group type: EXPERIMENTAL
Intervention: 2 hours of daily patching with active vision therapy
Number of subjects: 19

Group type: COMPARATOR
Intervention: 2 hours of daily patching with placebo vision therapy
Number of subjects: 19
Study: 21042047

Group type: EXPERIMENTAL
Intervention: Dual-task (DT) group (stepping exercise in DT conditions, n=26)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Single-task (ST) group (stepping exercise in ST conditions, n=27)
Number of subjects: 53
Study: 19500724

Group type: EXPERIMENTAL
Intervention: Open-ended question without social desirability bias
Number of subjects: 312

Group type: COMPARATOR
Intervention: Closed-ended question without social desirability bias
Number of subjects: 312

Group type: COMPARATOR
Intervention: Open-ended question with social desirability bias
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Follow-up questions for all groups
Number of subjects: 312
Study: 16751018

Group type: EXPERIMENTAL
Intervention: omalizumab
Number of subjects: 19

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 19
Study: 15559530

Group type: EXPERIMENTAL
Intervention: Proton pump inhibitor-based first line triple therapies
Number of subjects: 25644

Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate based regimens
Number of subjects: 25644

Group type: EXPERIMENTAL
Intervention: H2 blockers-based therapies
Number of subjects: 25644

Group type: EXPERIMENTAL
Intervention: Proton pump inhibitor-based double combinations
Number of subjects: 25644

Group type: EXPERIMENTAL
Intervention: Clarithromycin+amoxicillin/nitroimidazole combinations
Number of subjects: 25644

Group type: EXPERIMENTAL
Intervention: Amoxicillin-nitroimidazole regimens
Number of subjects: 25644

Group type: EXPERIMENTAL
Intervention: Second-line triple regimens
Number of subjects: 25644

Group type: EXPERIMENTAL
Intervention: Quadruple therapies (first-line)
Number of subjects: 25644

Group type: EXPERIMENTAL
Intervention: Quadruple therapies (second-line)
Number of subjects: 25644
Study: 11426363

Group type: EXPERIMENTAL
Intervention: Low-dose aprotinin (30,000 KIU/kg added to pump prime, 15,000 KIU/kg every hour during cardiopulmonary bypass)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cell saver system (used to collect all blood at the operation site)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (routine management including collection of autologous blood)
Number of subjects: 60
Study: 9276107

Group type: EXPERIMENTAL
Intervention: Left vagal nerve stimulation (VNS)
Number of subjects: 10
Study: 7643542

Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment (AHT) - angiotensin converting enzyme inhibition for 6 (2 to 15) years
Number of subjects: 42
Study: 2745908

Group type: EXPERIMENTAL
Intervention: Goal-Setting/Goal Attainment group (GSGA, n=19)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Goal-Setting group (GS, n=19)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (n=22)
Number of subjects: 60
Study: 336305

Group type: EXPERIMENTAL
Intervention: Aerosolized fenoterol 400 microgram
Number of subjects: 31

Group type: COMPARATOR
Intervention: Isoproterenol 150 microgram
Number of subjects: 31
Study: 30812036

Group type: EXPERIMENTAL
Intervention: No mechanical bowel preparation (MBP)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Routine mechanical bowel preparation (MBP)
Number of subjects: 80
Study: 28153510

Group type: EXPERIMENTAL
Intervention: Electrical pudendal nerve stimulation
Number of subjects: 120

Group type: COMPARATOR
Intervention: Transvaginal electrical stimulation
Number of subjects: 120
Study: 24317122

Group type: EXPERIMENTAL
Intervention: Exercise intervention starting 2 weeks before admission and ending 6-8 weeks after discharge.
Number of subjects: 105
Study: 22874485

Group type: EXPERIMENTAL
Intervention: Angiotensin converting enzyme inhibitors (ACEIs)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Diuretics
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study: 20090327

Group type: EXPERIMENTAL
Intervention: Resin infiltration followed by fluoride varnish (2.26% F) application
Number of subjects: 50

Group type: COMPARATOR
Intervention: Fluoride varnish only
Number of subjects: 50
Study: 18559556

Group type: EXPERIMENTAL
Intervention: Curcumin 10 g
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Curcumin 12 g
Number of subjects: 12
Study: 16176340

Group type: EXPERIMENTAL
Intervention: Landiolol (short‐acting beta‐1‐adrenergic blocker)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (0.9% saline)
Number of subjects: 40
Study: 12639033

Group type: EXPERIMENTAL
Intervention: Household water chlorination and storage in a special container
Number of subjects: 0

Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 0
Study: 10480199

Group type: EXPERIMENTAL
Intervention: Family strategies intervention
Number of subjects: 87
Study: 8562214

Group type: EXPERIMENTAL
Intervention: Por La Vida intervention
Number of subjects: 512

Group type: COMPARATOR
Intervention: Community Living Skills (Control)
Number of subjects: 512
Study: 2118879

Group type: EXPERIMENTAL
Intervention: 10 micrograms IFN-gamma
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 100 micrograms IFN-gamma
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 500 micrograms IFN-gamma
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Repeated application of the same dose
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Changes in TNF serum levels
Number of subjects: 5
Study: 626496

Group type: EXPERIMENTAL
Intervention: Bacampicillin
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Pivampicillin
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Amoxycillin
Number of subjects: 11

Group type: COMPARATOR
Intervention: Ampicillin
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Bacampicillin and Pivampicillin
Number of subjects: 11
Study: 31957922

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 100 U
Number of subjects: 248

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 248
Study: 31759966

Group type: EXPERIMENTAL
Intervention: LAMA-LABA-ICS
Number of subjects: 8853

Group type: COMPARATOR
Intervention: LAMA-LABA
Number of subjects: 8853
Study: 27930924

Group type: EXPERIMENTAL
Intervention: Radium-223
Number of subjects: 881

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 881
Study: 25550349

Group type: EXPERIMENTAL
Intervention: Oral amoxicillin
Number of subjects: 527

Group type: COMPARATOR
Intervention: Benzyl penicillin
Number of subjects: 527

Group type: EXPERIMENTAL
Intervention: Overall mortality
Number of subjects: 527

Group type: EXPERIMENTAL
Intervention: Presence of wheeze
Number of subjects: 527
Study: 23758661

Group type: EXPERIMENTAL
Intervention: 2 minutes of daily progressive resistance training with elastic tubing
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: 12 minutes of daily progressive resistance training with elastic tubing
Number of subjects: 198

Group type: COMPARATOR
Intervention: Control group receiving weekly information on general health
Number of subjects: 198
Study: 19858350

Group type: EXPERIMENTAL
Intervention: Music intervention (self-selected music of 60-80 beats per minute for 30 minutes)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation (PMR) intervention (pre-recorded audio of instructions for 16 muscle groups)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 72
Study: 17093146

Group type: EXPERIMENTAL
Intervention: Lupin kernel flour-enriched bread (LB) breakfast
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Lupin kernel flour-enriched bread (LB) lunch
Number of subjects: 33

Group type: COMPARATOR
Intervention: White bread (WB) breakfast
Number of subjects: 33

Group type: COMPARATOR
Intervention: White bread (WB) lunch
Number of subjects: 33
Study: 14985224

Group type: EXPERIMENTAL
Intervention: 400 micro g folic acid
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: 416 micro g [6S]-5-MTHF
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: 208 micro g [6S]-5-MTHF
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study: 11134430

Group type: EXPERIMENTAL
Intervention: Recombinant granulocyte colony-stimulating factor (rG-CSF) 10 microgram/kg/day IV once daily for 3 days
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo (visually indistinguishable vehicle)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Recombinant granulocyte colony-stimulating factor (rG-CSF)
Number of subjects: 44
Study: 9253572

Group type: EXPERIMENTAL
Intervention: Antiseptic-impregnated catheter (silver sulphadiazine and chlorhexidine)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Standard polyurethane catheter
Number of subjects: 79
Study: 8487664

Group type: EXPERIMENTAL
Intervention: ACIPIMOX
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: HEPARIN
Number of subjects: 10

Group type: COMPARATOR
Intervention: NIL
Number of subjects: 10
Study: 2887951

Group type: EXPERIMENTAL
Intervention: octreotide (SMS 201-995)
Number of subjects: 14

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 14
Study: 29392419

Group type: EXPERIMENTAL
Intervention: Growing steers (n = 6)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Finished steers (n = 4)
Number of subjects: 8
Study: 27143350

Group type: EXPERIMENTAL
Intervention: Health coaching intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 0
Study: 24439136

Group type: EXPERIMENTAL
Intervention: Tigecycline (150 mg once-daily)
Number of subjects: 944

Group type: COMPARATOR
Intervention: Ertapenem ± vancomycin (1 g once-daily)
Number of subjects: 944
Study: 23011489

Group type: EXPERIMENTAL
Intervention: 6-month, 3 times per week exercise intervention
Number of subjects: 140
Study: 20729688

Group type: EXPERIMENTAL
Intervention: Low-pressure (8 mm Hg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Standard-pressure (12 mm Hg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: High-pressure (14 mm Hg)
Number of subjects: 60
Study: 19128258

Group type: EXPERIMENTAL
Intervention: Topical basic fibroblast growth factor (bFGF)
Number of subjects: 0
Study: 15735613

Group type: EXPERIMENTAL
Intervention: Immediate-release metoprolol
Number of subjects: 80
Study: 12525515

Group type: EXPERIMENTAL
Intervention: Surgery plus fluorouracil (FU)-leucovorin chemotherapy (431 patients)
Number of subjects: 706

Group type: COMPARATOR
Intervention: Surgery alone (275 patients)
Number of subjects: 706
Study: 11012951

Group type: EXPERIMENTAL
Intervention: Parental presence during anaesthesia induction
Number of subjects: 73
Study: 8780417

Group type: EXPERIMENTAL
Intervention: Desipramine (200 mg daily)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 1363375

Group type: EXPERIMENTAL
Intervention: 75 mg of propranolol
Number of subjects: 28

Group type: COMPARATOR
Intervention: 30 mg of diazepam
Number of subjects: 28
Study: 6469178

Group type: EXPERIMENTAL
Intervention: Trigastril 50 Del
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Maaloxan Suspension
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Kompensan‐S forte Suspension
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Solugastril 50 Gel
Number of subjects: 6